NRAS and melanoma: In primary melanoma, mutations in RAS and RAF are mutually exclusive [4], but after vemurafenib treatment failure, it was identified a new mutation in the NRAS kinase, causing the reactivation of the MAPK pathway and disease progression [99] (Figure 2(b)).